Literature DB >> 12970125

Tissue factor, thrombin, and cancer.

Frederick R Rickles1, Steven Patierno, Patricia M Fernandez.   

Abstract

In addition to its primary role in hemostasis and blood coagulation, thrombin is a potent mitogen capable of inducing cellular functions. Therefore, it should come as no surprise that thrombin has proved to be of importance in the behavior of cancer. In this review, we focus on the ability of tissue factor (TF) and thrombin to influence tumor angiogenesis. Both exert their influence on angiogenesis through clotting-dependent and clotting-independent mechanisms: (1). directly affecting signaling pathways that mediate cell functions, and (2). mediating clot formation, thereby providing a growth media for tumor cells. Therefore, anticoagulant drugs may prove efficacious in cancer treatment due to their ability to reduce the characteristic hypercoagulability of cancer and alter the fundamental biology of cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970125     DOI: 10.1378/chest.124.3_suppl.58s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  87 in total

1.  Malignancy and hypercoagulability: a two-way association revisited.

Authors:  Elie G Aoun; Khaled M Musallam; Mohamad Abou-Ghazal; Ali T Taher
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

Review 2.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Authors:  Maya Zigler; Takafumi Kamiya; Emily C Brantley; Gabriel J Villares; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2011-10-18       Impact factor: 12.701

Review 3.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

Review 4.  The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.

Authors:  Guru Sonpavde; Joaquim Bellmunt; Fabio Schutz; Toni K Choueiri
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

5.  Cholangiocarcinoma: another masquerader in the making?

Authors:  Karthik Gnanapandithan; Satya Allaparthi; Thomas Ukena; Curuchi Anand
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 6.  Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.

Authors:  Ning Zhang; Weihua Lou; Fang Ji; Lihua Qiu; Benjamin K Tsang; Wen Di
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

7.  Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

Authors:  Eric T Alexander; Allyson R Minton; Candace S Hayes; Ashley Goss; Joanne Van Ryn; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Cardiac fibroblasts support endothelial cell proliferation and sprout formation but not the development of multicellular sprouts in a fibrin gel co-culture model.

Authors:  Rachel L Twardowski; Lauren D Black
Journal:  Ann Biomed Eng       Date:  2014-01-17       Impact factor: 3.934

9.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

10.  Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.

Authors:  Jessica S Blackburn; Constance E Brinckerhoff
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.